V5Med Lung AI

V5Med Lung AI is an advanced artificial intelligence solution designed to support early detection and accurate diagnosis of lung cancer through low-dose computed tomography (LDCT) scans. Built on cutting-edge deep learning and trained with diverse clinical datasets, the platform enhances radiologists’ capabilities by improving sensitivity, reducing false positives, and streamlining the diagnostic process.

Lung cancer is the leading cause of cancer-related deaths worldwide, largely because it is often diagnosed in late stages. Early detection through LDCT screening significantly improves survival rates. However, the process of analyzing thousands of chest images is time-consuming, complex, and prone to human fatigue and oversight.

V5 Lung AI transforms LDCT lung screening by:

• Automated Nodule Detection Identifies, segments, and characterizes lung nodules with high precision.
• Risk Stratification Differentiates between benign and malignant findings to support clinical decision-making.
• Workflow Integration Seamlessly integrates into hospital PACS/RIS systems to assist radiologists in real-time.
• Enhanced Reporting Generates structured, evidence-based reports to standardize patient management.
  
  

  Key Benefits

  ✔ Early & Accurate Detection – Improves sensitivity for small nodules while reducing false alarms.
  ✔ Time Efficiency – Cuts down radiologist reading time for LDCT scans.
  ✔ Clinical Confidence – Provides explainable AI outputs that complement physician expertise.
  ✔ Scalability – Adaptable for population-wide lung cancer screening programs.
  ✔ Patient Outcomes – Enables earlier intervention, increasing survival rates and reducing treatment costs.
  
  

  Who Can Benefit?

  • Hospitals & Screening Centers – Improve screening efficiency and accuracy.
  • Radiologists & Oncologists – Support clinical workflow with AI-powered second reading.
  • Public Health Programs – Enable scalable, population-level early detection initiatives.
  • Patients – Gain earlier diagnoses and better treatment opportunities.